Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURELIO-05: SOT101 plus cetuximab in RAS wild-type colorectal cancer
2022-001527-32Phase 2Active
- Sponsor
- SOTIO Biotech
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanrilkefusp alfa and cetuximab in colorectal cancer (CRC), sponsored by SOTIO Biotech. Primary endpoint: Objective response rate (ORR, RECIST 1.1). Started Jul 2022; status: active.
02
Drugs
nanrilkefusp alfacetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2022-001527-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001527-32.